Categories: News

Vistin Pharma ASA: Key information relating to the proposed cash dividend

The Board of Directors of Vistin Pharma ASA (VISTN) will propose to distribute a cash dividend of total NOK 1.25 per share, to be paid in June, for the accounting year of 2024. The formal decision regarding the dividend will be made on the company’s Annual General Meeting, which will be held on 22 May 2025.

Dividend amount (per share): NOK 1.25

Declared currency: NOK

Last day including right: 3 June 2025

Ex-date: 4 June 2025

Record date: 5 June 2025

Payment date (on or about): 12 June 2025

Date of approval: 22 May 2025

For further information, please contact:

Alexander Karlsen

CFO

+47 97 05 36 21

alexander.karlsen@vistin.com

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Staff

Recent Posts

Restart Life Sciences Signs Binding LOI to Acquire The Holy Crap Foods Portfolio of Brands and Manufacturing Plant

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

37 minutes ago

Functional Brands Inc. Launches Kirkman’s(R) Skin, Beauty & Anti-Aging Bundle: A Science-Backed Approach to Radiant, Resilient Skin

Comprehensive Formula Featuring Reduced Glutathione, Zinc Cream, Biotin, and Grapefruit Seed ExtractLake Oswego, Oregon--(Newsfile Corp.…

37 minutes ago

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces…

2 hours ago

XRP Healthcare® Secures Global Trademark Protection at the Intersection of Healthcare Services and XRP-Powered Payments

Multi-jurisdiction trademark coverage reinforces XRP Healthcare's position across digital health, pharmacy networks, and XRP-based payment…

3 hours ago

Black Book Poll: “Governed AI” Emerges as the Deciding Factor in 2026 NHS Procurement

Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety…

3 hours ago

Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the…

3 hours ago